Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Exclusion Criteria

• •a. Anti-tumor molecular target therapy; anti-tumor chemotherapy in 6 months; b. lesions have been treated by irradiation; c. participate in other therapeutic or interventional clinical trials.
• •Have central nervous system metastasis;
• •* History of other malignancies except carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and other malignancies for more than 5 years;
• •* Have symptomatic ascites and need for treatment;
• •* Have serious concurrent illness including, but not limited to
• •1. uncontrolled congestive heart failure(NYHA classification grade III or IV), unstable angina pectoris, unstable cardiac arrhythmias, uncontrolled moderate or serious hypertension(systolic blood pressure \>21.3 Kpa or diastolic blood pressure \>13.3 Kpa);
• •2. ongoing or active serious infection;
• •3. uncontrolled diabetes mellitus;
• •4. psychiatric illness which potentially hamper the ability to willingly give written informed consent and compliance with the study protocol;
• •5. HIV infection;
• •6. other serious illness considered not suitable for this study by investigators.
• •* be allergic or have contraindications to target medicines involved in this study, gemcitabine or oxaliplatin.